Meadow Creek Investment Management LLC cut its stake in shares of bluebird bio Inc (NASDAQ:BLUE) by 13.7% in the 4th quarter, HoldingsChannel reports. The fund owned 9,680 shares of the biotechnology company’s stock after selling 1,540 shares during the period. Meadow Creek Investment Management LLC’s holdings in bluebird bio were worth $1,724,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of BLUE. BlackRock Inc. boosted its position in shares of bluebird bio by 6.4% during the fourth quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock valued at $682,366,000 after buying an additional 231,697 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of bluebird bio by 41.3% during the fourth quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock valued at $122,337,000 after buying an additional 200,900 shares during the last quarter. Orbimed Advisors LLC boosted its position in shares of bluebird bio by 20.5% during the third quarter. Orbimed Advisors LLC now owns 481,946 shares of the biotechnology company’s stock valued at $66,195,000 after buying an additional 82,146 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of bluebird bio by 3,004.0% during the fourth quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock valued at $82,371,000 after buying an additional 447,600 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of bluebird bio by 9.0% during the fourth quarter. Geode Capital Management LLC now owns 454,997 shares of the biotechnology company’s stock valued at $81,034,000 after buying an additional 37,588 shares during the last quarter.
bluebird bio stock opened at $199.80 on Monday. The stock has a market capitalization of $9,986.71, a PE ratio of -26.08 and a beta of 2.06. bluebird bio Inc has a 12-month low of $74.45 and a 12-month high of $236.17.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.84). The firm had revenue of $4.17 million during the quarter, compared to analysts’ expectations of $7.11 million. bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The company’s revenue for the quarter was up 169.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.88) earnings per share. analysts anticipate that bluebird bio Inc will post -8.4 EPS for the current fiscal year.
In other news, insider Jason Cole sold 1,129 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $173.38, for a total value of $195,746.02. Following the transaction, the insider now owns 19,945 shares of the company’s stock, valued at $3,458,064.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Davidson sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $180.30, for a total value of $1,081,800.00. Following the completion of the transaction, the insider now directly owns 21,977 shares in the company, valued at approximately $3,962,453.10. The disclosure for this sale can be found here. Insiders sold 64,598 shares of company stock worth $12,370,309 over the last three months. Insiders own 3.90% of the company’s stock.
Several equities research analysts recently commented on the company. William Blair reaffirmed a “buy” rating on shares of bluebird bio in a research report on Friday. UBS assumed coverage on bluebird bio in a research report on Friday. They set a “sell” rating on the stock. BidaskClub cut bluebird bio from a “strong-buy” rating to a “buy” rating in a research report on Friday. Janney Montgomery Scott assumed coverage on bluebird bio in a research report on Wednesday, March 14th. They set a “neutral” rating and a $220.00 price objective on the stock. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $250.00 price objective on shares of bluebird bio in a research report on Tuesday, March 13th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. bluebird bio has an average rating of “Hold” and an average price target of $192.35.
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/03/19/meadow-creek-investment-management-llc-has-1-72-million-stake-in-bluebird-bio-inc-blue.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.